Eisai stock rises after strong Leqembi sales boost quarterly results

Published 05/08/2025, 09:44
 Eisai stock rises after strong Leqembi sales boost quarterly results

Investing.com -- Eisai Co (OTC:ESAIY). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its Alzheimer’s drug Leqembi.

The Japanese pharmaceutical company reported that global Leqembi sales expanded 269% YoY to ¥23.1 billion in the first quarter. However, this impressive growth included ¥5.3 billion in one-off demand from China, which was previously signaled by partner Biogen (NASDAQ:BIIB) in its recent earnings report. Adjusting for this special demand, underlying Leqembi sales grew 84% to ¥17.8 billion.

Regional performance showed Japan sales of Leqembi reached ¥5.5 billion, up ¥4 billion YoY, achieving 23% of the company’s full-year guidance of ¥24 billion. In the Americas, sales grew 98% YoY to ¥9.1 billion, representing 23% of the ¥40 billion annual target. China sales were particularly strong at ¥7.7 billion, with underlying sales of approximately ¥2.4 billion, putting the company on track to exceed its full-year China guidance of ¥9.5 billion.

The company’s anticancer drug Lenvima saw more modest growth, with sales increasing by ¥0.4 billion to ¥83.9 billion, reaching 27% of the full-year target.

Eisai maintained cost discipline during the quarter, with gross profit margin holding steady at 79% YoY. The SG&A ratio improved to 49.4% from 52.7% in the same quarter last year, helping operating profit margin rise to 10.2% from 7.1% a year earlier.

Jefferies analysts noted: "we judge underlying profits to be just in line, because ¥5.3bn of extraordinary Leqembi demand likely accounts for the majority of the ¥2.9bn OP beat versus consensus."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.